Scarica l'app Stockscreener
5.99
2.92%
-0.18
Dopo l'orario di chiusura:
5.73
-0.26
-4.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Precedente Chiudi:
$6.17
Aprire:
$6.05
Volume 24 ore:
803.29K
Relative Volume:
0.42
Capitalizzazione di mercato:
$24.37M
Reddito:
-
Utile/perdita netta:
$-54.66M
Rapporto P/E:
-0.3141
EPS:
-19.0729
Flusso di cassa netto:
$-49.98M
1 W Prestazione:
+204.06%
1M Prestazione:
+172.27%
6M Prestazione:
-53.60%
1 anno Prestazione:
+16.76%
Intervallo 1D:
$5.6801
$6.50
Intervallo di 1 settimana:
$1.70
$9.90
Portata 52W:
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Nome
Nextcure Inc
Settore
Industria
Telefono
240-399-4900
Indirizzo
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
5.99 | 25.11M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-03-05 | Aggiornamento | Truist | Hold → Buy |
| 2021-01-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Downgrade | SunTrust | Buy → Hold |
| 2020-06-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-03-24 | Iniziato | The Benchmark Company | Buy |
| 2020-03-02 | Iniziato | ROTH Capital | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-05 | Iniziato | Needham | Buy |
| 2019-11-26 | Iniziato | BTIG Research | Buy |
| 2019-07-09 | Iniziato | BofA/Merrill | Buy |
| 2019-06-03 | Iniziato | Morgan Stanley | Overweight |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Nextcure Inc Borsa (NXTC) Ultime notizie
NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NextCure and Avere Therapeutics Announce Merger and $320 Million Private Financing - Global Legal Chronicle
NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan - Stock Titan
NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny - StocksToTrade
H.C. Wainwright reiterates NextCure stock rating on merger news - Investing.com
H.C. Wainwright reiterates NextCure stock rating on merger news By Investing.com - Investing.com UK
Beltsville's NextCure merging with San Francisco startup - The Business Journals
Dow Falls Over 100 Points Following Inflation Data; Crude Oil Gains - Sahm
NextCure Announces Transformative All-Stock Merger With Avere - TipRanks
NextCure, Avere Therapeutics enter definitive merger agreement - TipRanks
Law firm investigates if NextCure shareholders get a fair price in merger with Avere Therapeutics. - Pluang
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - GlobeNewswire Inc.
Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis - insights.citeline.com
After $5 billion-plus Novo Nordisk buyout, this biotech band is playing an encore with big merger plans - The Business Journals
Power Moves: NXTC, TOON, SHPH, COCH Entry Points Ignite on Major Catalysts - FinancialContent
Why Did NextCure Stock 3X In One Session?NextCure (NASDAQ:NXTC) - Benzinga
Law firm investigates NextCure merger fairness as shareholders get 1.21% stake in combined company - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) - PR Newswire
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
NextCure, Inc. (NXTC) Stock: Soars 218% After Avere Merger and $320M Private Placement Deal - parameter.io
NextCure stock surge puts cash payout and 1.21% Avere stake under the lens - TechStock²
NextCure faces investigation over merger terms with Avere Therapeutics amid shareholder concerns. - Pluang
NextCure and Avere Therapeutics Announce $320M Merger to Advance Once-Weekly Oral IL-23 Therapy for Psoriasis and Ulcerative Colitis 12 – Minichart - Minichart
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan - Quiver Quantitative
NextCure backs Avere merger with $320 million financing - grafa.com
Avery Therapeutics, Inc. entered into a definitive merger agreement to acquire NextCure, Inc. for $250 million in a reverse merger transaction. - marketscreener.com
NXTC Stock Rockets On Massive Volume As Traders Pile In - StocksToTrade
NextCure to merge with Avere Therapeutics in $320M deal By Investing.com - Investing.com Australia
NextCure (NXTC) Stock Skyrockets 300% Following $320M Avere Therapeutics Merger Agreement - parameter.io
NextCure (NXTC) Stock Rockets 300% Following $320M Avere Therapeutics Merger Announcement - MoneyCheck
NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement - Blockonomi
NextCure (NXTC) Stock Surges 300% on $320M Merger Deal With Avere Therapeutics - CoinCentral
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
NextCure and Avere Therapeutics Merge, Raise $320 Million to Advance Oral IL-23 Program - citybiz
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill - Yahoo Finance
NextCure to merge with privately-held Avere (NXTC:NASDAQ) - Seeking Alpha
NextCure (NASDAQ: NXTC) plans reverse merger; Avere holders to own about 98% - Stock Titan
NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company - TradingView
NextCure (NASDAQ: NXTC) sets Avere merger backed by $320M raise - Stock Titan
NextCure to merge with Avere Therapeutics in $320M deal - Investing.com
NextCure and Avere Therapeutics Announce Definitive Merger and $320 Million Financing to Advance Oral IL-23 Therapy AVR-001 - Quiver Quantitative
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy - The Manila Times
After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug - Endpoints News
What's going on with NextCure stock Wednesday? - MSN
Price to sales forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
Price to sales forward of NextCure, Inc. – LSX:A41AKJ - TradingView
Enterprise value to EBITDA forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
Enterprise value to EBITDA forward of NextCure, Inc. – MUN:2US0 - TradingView
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Nextcure Inc Azioni (NXTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):